which can, over time,
Introduction studied. In the this paper we present the results of our interim analysis after 1-year follow up. Continuous peritoneal dialysis is associated with a risk of peritonitis and changes in the peritoneal membrane icodextrin or glucose for the daytime dwell (14-15 h). Both users. After 3, 6 and 9 months a significant difference established CCPD patients and patients new to CCPD were in ultrafiltration between glucose and icodextrin users included. The patients had to be compliant, in a stable existed (ANOVA glucose versus icodextrin from baseclinical condition (no peritonitis in the previous month) with line: P∏0.01). The total (24-h) ultrafiltration volumes an estimated life expectancy of more than 2 years, and aged were also larger in icodextrin users at all visits over 18. Women of child-bearing potential were excluded (Table 1 ) , but a significant difference between the unless taking adequate contraceptive precautions. The study groups was not reached. Within the icodextrin group was approved by the local ethical commitee and written the total ultrafiltration increased significantly from informed consent was obtained from each patient.
baseline at 3 and 6 months (P=0.02).
Clinic visits were made every 3 months. Icodextrin was manufactured and supplied by ML Laboratories plc. (St The glucose concentrations used during the nightAlbans, UK ). It was bagged as 2-litre 7.5% w/v by Fresenius time CCPD cycles at baseline, were similar in glucose AG, Bad Homburg, Germany. The glucose solutions were patients and icodextrin patients (average glucose conthose commercially available from Baxter BV ( Utrecht, The centrations 2.34±0.24 versus 2.29±0.18% respectively; Netherlands). These were bagged as 2-litre 1.36, 2.27 or NS). However, the glucose concentrations used during 3.86% w/v solution. Ultrafiltration volumes were recorded CCPD cycles tended to increase over time in both automatically by the patients' CCPD machines and tran-groups ( Table 2 ) (Table 3 ) . This difference only disapwithin the groups using a one-way analysis of variance peared when the dialysate clearance was corrected for ( ANOVA). Group differences were tested using a paired two-tailed Student's t test. Analysis was done in SPSSB for the ultrafiltration in litres (data not shown in Table 3 ).
WindowsTM 6.01. P<0.05 was considered to be significant.
Urine creatinine clearance (Table 3 ) and diuresis ( P∏0.005, within the group), this in contrast to glucose Table 1 . Mean ultrafiltration volume and diuresis (±SEM ) in glucose (G ) and icodextrin (I ) users during 12-months follow up
#P∏0.02, G versus I from baseline ( ANOVA). Note. At study entry three patients ( 1 G and 2 I ) had a dry abdomen during the daytime because of previous ultrafiltration failure. Zero daytime dwell ultrafiltration was taken in these patients.
N. Posthuma et al. 552 Table 3 . Mean (±SEM ) serum creatinine concentration, dialysate creatinine clearance, and urine creatinine clearance in CCPD patients using glucose (G ) or icodextrin ( I ) not reach statistical significance (nor the decrease from dwell in CAPD. As shown in Table 1 , daytime ultrafiltration increased markedly in icodextrin patients at all baseline, nor the difference between the groups). Total creatinine clearance (dialysate and urine combined) intervals. At 12 months follow-up however, it was not statistically different from glucose users. This may in fluctuated around baseline in the glucose users and was higher at all follow-up visits in icodextrin users, part be explained by the number of patients in the study. During the study period, total ultrafiltration but was not significant.
Body-weight remained stable in glucose patients increased after initiation of icodextrin treatment, but because of the large interindividual variation in ultra-( 71.9±3.4 kg at baseline and 72.4±3.9 kg after 12 months), and increased in icodextrin patients filtration, the difference compared with glucose-treated patients did not reach statistical significance. Within ( 73.7±3.5 kg to 76.6±3.5 kg; NS). Mean arterial pressure decreased significantly after 6 months in glucose the icodextrin patients there was a significant increase from baseline up to 9 months. In addition, six patients users and remained stable in icodextrin patients ( 105±3 to 93±4 mmHg, P∏0.03 and 102±5 to adjusted their dialysis schedule according to their social needs after starting on icodextrin. Usually they 101±6 mmHg respectively). At the same time antihypertensive medication prescription decreased in glucose increased their daytime dwell volume and they skipped one exchange in the night, resulting in a constant patients and tended to increase in icodextrin patients.
No clinical side-effects or complaints were associated amount of used litres dialysate. As can be deduced from Table 2 , patients used the UF gain to drink more with icodextrin. Serum disaccharide levels increased in the icodextrin group from 0.049±0.01 to a steady state instead of decreasing their glucose concentration.
Diuresis did not decrease significantly during followof 1.20±0.2 g/l.
up in both groups, despite a larger ultrafiltration volume in icodextrin patients. Total fluid loss (diuresis Discussion and ultrafiltration) can be seen in Table 1 . It increased in icodextrin patients and decreased in glucose patients from baseline (1520±180 to 1615±188 ml In a previous randomized multicentre clinical trial, and 1593±181 to 1499±187 ml respectively). It is also isosmolar icodextrin was compared with hyperosmolar worth noticing that the three patients who had a dry glucose solutions in CAPD [6 ] . Long-term safety and abdomen during the day ( because of ultrafiltration efficacy were evaluated by comparing overnight use of failure) were recorded as having a zero daytime dwell icodextrin with conventional glucose exchanges over a ultrafiltration at study entry. These patients would period of 6 months. The mean ultrafiltration with definitively have had a large negative daytime dwell icodextrin was similar to that of 3.86% glucose at 8 ultrafiltration if so tested with glucose. Therefore, the and 12 h. Furthermore, a small drop in serum sodium difference between the icodextrin and glucose groups and chloride concentrations in the icodextrin group regarding the gain in daytime ultrafiltration is, at least occurred, together with a rise in the serum maltose theoretically, even larger. level. None of these findings was associated with any D CL /1.73 m2 increased as did the D Cl /1.73 m2/l, the adverse clinical effects. Using icodextrin instead of latter being a more accurate way of describing the glucose neither increased or decreased the peritonitis clearance for a certain dialysis fluid. The increase rate, nor alter the outcome of it [10] .
in clearance was approximately identical to the gain in So far, the published experience with icodextrin has ultrafiltration. When expressed as D Cl /1.73 m2/l/UF, been confined to CAPD over a period of 6 months.
the difference between glucose and icodextrin disapLong-term data and extended dwell periods are necespeared, indicating that the intrinsic clearance capability sary to further establish its safety and efficacy.
of icodextrin is probably the same as that of glucose, We compared in the present study icodextrin used and that the observed increase in 24-h UF, although for the daytime dwell in CCPD with glucose. The statistically not significant at all intervals, probably daytime dwell averaged 14 h 35 min in our study, which is considerably longer than the usual night-time accounts for the increase in clearance. The increase in measured D Cl is thus mainly due to 'colloid'-induced References osmotic convective transport. This is in accordance We conclude that the daytime dwell use of icodextrin Nephrol 1995; 6: 513 (abstract) in CCPD will significally increase daytime ultrafiltra- The effect of glucose polymers on water removal and protein
